CTOs on the Move

Taisho Pharmaceutical California

www.taisho.com

 
Taisho Pharmaceutical California is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.taisho.com
  • 3878 W Carson St Ste 216
    Torrance, CA USA 90503
  • Phone: 310.543.2035

Executives

Name Title Contact Details

Similar Companies

Prinston Pharm

Maker of high quality and affordable generic pharmaceutical products

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Havas Health and You

Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Infinant Health

Infinant Health is a life sciences company that is committed to changing the trajectory of human health, one baby at a time, through their deep understanding of infant nutrition and the gut microbiome.